Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Operating Leases (2019 - 2025)

Corcept Therapeutics (CORT) has disclosed Operating Leases for 6 consecutive years, with $5.0 million as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 17.75% to $5.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.0 million through Dec 2025, down 17.75% year-over-year, with the annual reading at $5.0 million for FY2025, 17.75% down from the prior year.
  • Operating Leases hit $5.0 million in Q4 2025 for Corcept Therapeutics, down from $5.3 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $6.8 million in Q3 2024 to a low of $76000.0 in Q1 2024.
  • Historically, Operating Leases has averaged $3.4 million across 4 years, with a median of $2.8 million in 2022.
  • Biggest five-year swings in Operating Leases: crashed 86.88% in 2023 and later soared 7598.68% in 2025.
  • Year by year, Operating Leases stood at $1.1 million in 2022, then plummeted by 80.31% to $225000.0 in 2023, then skyrocketed by 2614.22% to $6.1 million in 2024, then dropped by 17.75% to $5.0 million in 2025.
  • Business Quant data shows Operating Leases for CORT at $5.0 million in Q4 2025, $5.3 million in Q3 2025, and $6.6 million in Q2 2025.